SYNC
NEUTRALSyncona Limited Publishes 2025 Annual Report and Notice of AGM
The life science investor has published its annual report and notice of AGM for 2025.
Syncona Limited
95.69GBX
0.31%
Market Cap
581.69M
Volume
133.43k
28% of avg
P/E Ratio
5.32
EPS (TTM)
0.18
Beta
0.2
Day Range
95.40p - 96.88p
52 Week Range
77.32p95.69p126.00p
95.69p
Upcoming Events
SYNC
BADSyncona Reports Challenging Year Amid Biotech Sector Headwinds
This investment company faced a challenging year with a 9.5% decline in NAV per share and a 17% negative return on its life science portfolio, reflecting broader biotech sector headwinds and volatile market conditions.
SYNC
NEUTRALSyncona Announces Strategic Review and Proposed Changes
The asset management firm is undertaking a strategic review and proposing changes to its investment objective and policy to maximize shareholder value.
SYNC
NEUTRALSyncona's Portfolio Company Autolus Presents Long-Term Data on Obe-Cel for R/R B-ALL
The biopharmaceutical company Autolus, a portfolio company of Syncona, will present updated long-term data on its obe-cel therapy for r/r B-ALL at the EHA Congress.
SYNC
NEUTRALSyncona Limited Announces Holding Change
The investment company has received a notification of a change in shareholding from BlackRock, Inc.
SYNC
NEUTRALSyncona's Portfolio Company Spur Therapeutics Presents Positive Data at ASGCT
The biotechnology company presents positive data on its gene therapy programs for Gaucher disease, Parkinson's disease, and adrenomyeloneuropathy at a medical conference.
SYNC
GOODAutolus Therapeutics Reports Strong Q1 2025 Results, Expands AUCATZYL into UK
The biopharmaceutical company reported robust Q1 2025 results, including $9.0 million in net product revenue, and obtained UK marketing authorization for its lead product AUCATZYL.
SYNC
NEUTRALBeacon Therapeutics Announces Positive Phase 2 Data for XLRP Treatment
The biotechnology company reports positive interim results from a Phase II trial of its gene therapy for a rare inherited retinal disease.
SYNC
NEUTRALMosaic Therapeutics in-licenses two clinical-stage assets from Astex Pharmaceuticals
The targeted oncology therapeutics company Mosaic Therapeutics has in-licensed two clinical-stage assets from Astex Pharmaceuticals, accelerating its development pipeline.
SYNC
GOODAutolus Reports Full Year 2024 Financial Results
The biopharmaceutical company reports full year 2024 financial results, including increased cash position and progress on the commercial launch of its lead product AUCATZYL.